List of Prezista drug patents

Prezista is owned by Janssen Prods.

Prezista contains Darunavir.

Prezista has a total of 4 drug patents out of which 0 drug patents have expired.

Prezista was authorised for market use on 23 June, 2006.

Prezista is available in tablet;oral dosage forms.

The generics of Prezista are possible to be released after 26 June, 2027.

PREZISTA's oppositions filed in EPO
PREZISTA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(8 months from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(1 year, 2 months from now)

US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Jun, 2027

(4 years from now)

Do you want to check out PREZISTA patents from before 2022?

Drugs and Companies using DARUNAVIR ingredient

Market Authorisation Date: 23 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PREZISTA before it's patent expiration?
More Information on Dosage

PREZISTA family patents

8

United States

6

European Union

4

Spain

3

Denmark

3

Cyprus

3

Portugal

3

Slovenia

2

Korea, Republic of

2

Australia

1

Hong Kong

AP

1

AP

1

Poland

1

China

1

Brazil

1

Canada

EA

1

EA

1

Norway

1

Japan

1

New Zealand

1

Croatia

1

Mexico

1

South Africa

1

Lithuania

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in